Hoth Therapeutics, Inc. (HOTH)
HOTH Stock Price Chart
Explore Hoth Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze HOTH price movements and trends.
HOTH Company Profile
Discover essential business fundamentals and corporate details for Hoth Therapeutics, Inc. (HOTH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Feb 2019
Employees
2.00
Website
https://www.hoththerapeutics.comCEO
Robb Knie
Description
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
HOTH Financial Timeline
Browse a chronological timeline of Hoth Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
Earnings released on 12 Aug 2025
EPS came in at -$0.17 surpassing the estimated -$0.27 by +37.04%.
Earnings released on 12 May 2025
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%.
Earnings released on 28 Mar 2025
EPS came in at -$0.32 surpassing the estimated -$0.39 by +17.95%.
Earnings released on 12 Nov 2024
EPS came in at -$0.31 falling short of the estimated -$0.30 by -3.33%.
Earnings released on 9 Aug 2024
EPS came in at -$0.24 surpassing the estimated -$0.39 by +38.46%.
Earnings released on 14 May 2024
EPS came in at -$0.46 falling short of the estimated -$0.43 by -6.98%.
Earnings released on 28 Mar 2024
EPS came in at -$0.31 surpassing the estimated -$0.51 by +39.22%, while revenue for the quarter reached $59.54K .
Earnings released on 13 Nov 2023
EPS came in at -$0.60 surpassing the estimated -$0.72 by +16.67%.
Earnings released on 11 Aug 2023
EPS came in at -$0.57 surpassing the estimated -$1.16 by +50.86%.
Earnings released on 15 May 2023
EPS came in at -$0.88 falling short of the estimated -$0.86 by -2.33%.
Earnings released on 31 Mar 2023
EPS came in at -$2.72 falling short of the estimated -$2.29 by -18.78%.
Earnings released on 10 Nov 2022
EPS came in at -$2.05 surpassing the estimated -$2.39 by +14.23%.
Stock split effective on 26 Oct 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Aug 2022
EPS came in at -$2.25 matching the estimated -$2.25.
Earnings released on 12 May 2022
EPS came in at -$2.75 matching the estimated -$2.75.
Earnings released on 30 Mar 2022
EPS came in at -$3.50 falling short of the estimated -$3.00 by -16.67%.
Earnings released on 10 Nov 2021
EPS came in at -$3.50 surpassing the estimated -$3.75 by +6.67%.
Earnings released on 11 Aug 2021
EPS came in at -$3.50 surpassing the estimated -$4.50 by +22.22%.
Earnings released on 13 May 2021
EPS came in at -$6.00 falling short of the estimated -$2.50 by -140.00%.
Earnings released on 16 Mar 2021
EPS came in at -$1.00 surpassing the estimated -$2.50 by +60.00%.
Earnings released on 10 Nov 2020
EPS came in at -$4.00 falling short of the estimated -$3.25 by -23.08%.
HOTH Stock Performance
Access detailed HOTH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.